New Twice-Yearly injection shows promise in lowering bad cholesterol

NCT ID NCT05888103

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested a new injectable drug called inclisiran to see if it safely lowers 'bad' cholesterol (LDL-C) in Chinese adults. 207 participants with elevated cholesterol but low-to-moderate heart disease risk received either the drug or a placebo injection. The main goal was to see how much the drug reduced cholesterol levels over six months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Fuzhou, Fujian, 350025, China
Novartis Investigative Site

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site

Zhongshan, Guangdong, 528403, China
Novartis Investigative Site

Wuhan, Hubei, 430022, China
Novartis Investigative Site

Changsha, Hunan, 410003, China
Novartis Investigative Site

Changsha, Hunan, 410011, China
Novartis Investigative Site

Hohhot, Inner Mongolia, 010017, China
Novartis Investigative Site

Changzhou, Jiangsu, 213004, China
Novartis Investigative Site

Xuzhou, Jiangsu, 221003, China
Novartis Investigative Site

Nanchang, Jiangxi, 330009, China
Novartis Investigative Site

Jinzhou, Liaoning, 121001, China
Novartis Investigative Site

Linyi, Shandong, 276000, China
Novartis Investigative Site

Taiyuan, Shanxi, 030002, China
Novartis Investigative Site

Xian, Shanxi, 710061, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Tianjin, Tianjin Municipality, 300121, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310006, China
Novartis Investigative Site

Beijing, 100029, China
Novartis Investigative Site

Beijing, 100034, China
Novartis Investigative Site

Beijing, 100730, China
Novartis Investigative Site

Beijing, 101200, China
Novartis Investigative Site

Jinan, 250012, China
Novartis Investigative Site

Shanghai, 200025, China
Novartis Investigative Site

Shanghai, 200080, China
Novartis Investigative Site

Shanghai, 200120, China
Novartis Investigative Site

Tianjin, 300052, China
Novartis Investigative Site

Tianjin, 300140, China

Conditions

Explore the condition pages connected to this study.

PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA